NCT03922945: A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
- State
- Completed
- Phase
- Phase 4
- People
- 223 taking part
- Started
- 2 May 2019
- Primary completion
- 16 Apr 2021
- Arms
- VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg), VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)
- Results
- Posted on the registry
- 22 Apr 2019: Trial registered
- 2 May 2019: Trial started
- 16 Apr 2021: Trial completed
- 10 Sep 2022: Trial results posted